title: Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma.
abstract: From March 1985 to July 1989, 22 patients with unresectable pancreatic adenocarcinoma entered the study to receive external beam irradiation with chemotherapy. Radiation therapy consisted of 60 Gy in 3 courses (20 Gy each course) delivered over a period of 2 weeks, with a 2-week rest between the courses. Chemotherapy consisted of 5 fluorouracil, 500 mg/m2, plus cisplatinum, 20 mg/m2, administered on days 1, 2 and 3 of each radiation therapy course. Of the 22 evaluable patients, 10 were males and 12 females; their median age was 63 years (range, 32-77), and their median performance status was 80 (range, 60-90). After treatment, 12 partial remissions and 6 no changes were reported. In 4 cases, abdominal progression of disease during treatment required interruption of the therapy program. At the start of treatment, abdominal pain was the most important symptom in 17 patients; improvement of abdominal pain was observed in 10 cases (76%) after treatment and lasted for a median of 5 months. Median survival time was 7.5 months, and time to progression was 6.2 months. Median follow-up was 7 months (range, 14 days -38). In 2 cases, persistent hematologic toxicity did not permit completion of therapy, and in another 3 cases grade II hematologic toxicity required a 2-week rest period over the normal split-course program. In another 4 cases, grade I hematologic toxicity did not require any delay in the therapy program. Our results are comparable with those achieved in other major studies and are acceptable in terms of survival time, palliation of symptoms and toxicity. In our experience, the combination of radiotherapy plus 5-fluorouracil and cisplatinum does not seem to offer any advantage over the combination of radiation therapy and 5-fluorouracil.
authors.affiliation: Radiotherapy Dept., Centro di Riferimento Oncologico (C.R.O.), Aviano-Pordenone, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Boz
authors.forename: A
authors.initials: A
authors.lastname: De Paoli
authors.forename: M
authors.initials: M
authors.lastname: Roncadin
authors.forename: G
authors.initials: G
authors.lastname: Franchin
authors.forename: E
authors.initials: E
authors.lastname: Galligioni
authors.forename: M
authors.initials: M
authors.lastname: Arcicasa
authors.forename: R
authors.initials: R
authors.lastname: Bortolus
authors.forename: C
authors.initials: C
authors.lastname: Gobitti
authors.forename: E
authors.initials: E
authors.lastname: Minatel
authors.forename: R
authors.initials: R
authors.lastname: Innocente
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D059408:Pain Management; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*